| MYELODYSPLASTIC SYNDROME
Reblozyl vs Tibsovo
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Reblozyl vs Tibsovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTibsovo has a higher rate of injection site reactions vs Reblozyl based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tibsovo but not Reblozyl, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Reblozyl
Tibsovo
At A Glance
SC injection
Every 3 weeks
Erythroid maturation agent
Oral
Daily
IDH1 inhibitor
Indications
- beta Thalassemia
- MYELODYSPLASTIC SYNDROME
- Refractory anemia with ringed sideroblasts
- Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
Dosing
beta Thalassemia 1 mg/kg SC every 3 weeks; increase to max 1.25 mg/kg if no reduction in RBC transfusion burden after at least 2 consecutive doses at 1 mg/kg.
MYELODYSPLASTIC SYNDROME (ESA-naive) 1 mg/kg SC every 3 weeks; increase up to max 1.75 mg/kg to maintain hemoglobin 10 g/dL to 12 g/dL.
Refractory anemia with ringed sideroblasts, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (ESA-refractory or intolerant) 1 mg/kg SC every 3 weeks; increase to max 1.75 mg/kg if patient is not RBC transfusion-free.
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness, hypertension, nausea, edema peripheral, dyspnea, musculoskeletal pain
Serious thrombosis/thromboembolism, hypertension, extramedullary hematopoietic masses, cerebrovascular accident, deep vein thrombosis
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Pharmacology
Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and promoting erythroid maturation by increasing late-stage erythroid precursors (normoblasts) to reduce ineffective erythropoiesis in beta-thalassemia and MDS.
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Reblozyl
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
UnitedHealthcare
Reblozyl
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Reblozyl
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tibsovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ReblozylView full Reblozyl profile
TibsovoView full Tibsovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.